Patients starting cholesterol-lowering drugs in hospital take meds longer

November 24, 2003

CHICAGO - Starting patients on cholesterol-lowering drugs in the hospital instead of after they go home may increase the likelihood that they will continue taking their medications longer, according to an article in the November 24 issue of The Archives of Internal Medicine, one of the JAMA/Archives journals.

Despite data demonstrating the health benefits of lipid-lowering drugs (drugs that lower cholesterol levels) in patients with heart disease, these medicines remain underused, according to information in the article. Because lipid-lowering agents can improve cardiovascular health, strategies to increase their use are needed, the article states. Lipid-lowering therapy can be started when a patient is either in the hospital, or in an outpatient setting; it has been suggested that initiating therapy in the hospital may increase the probability that the patient adheres to the regimen for longer periods of time than if initiated outside the hospital.

Steven E. Nissen, M.D., of the Cleveland Clinic Foundation, and colleagues examined the relationship between when lipid-lowering therapy is initiated (during a hospital stay, or in an outpatient setting) and its long-term use.

The researchers used data from patients at 69 centers from the United States and Canada that participated in the Evaluation in PTCA to Improve Long-term Outcome With Abcix-imab GP IIb/IIIa Blockade (EPILOG) trial. The EPILOG trail involved patients hospitalized for treatment for heart disease who were randomized to receive placebo or lipid-lowering drugs. The patients were older than 21 years and were not taking lipid-lowering drugs when hospitalized. One hundred and seventy-five patients were discharged taking lipid-lowering therapy and 1,951 were discharged without lipid-lowering therapy.

The researchers found that after six months, 134 patients (77 percent) who started taking lipid-lowering agents before hospital discharge continued taking therapy compared with 494 (25 percent) of those discharged without lipid-lowering therapy, and who had these drugs prescribed by their doctors later.

"We found that initiation of lipid-lowering agents before discharge was the most important independent predictor of their use at follow-up," the authors write. "In fact, patients in whom lipid-lowering therapy was initiated before discharge were nearly three times as likely to be taking these agents six months later."

The researchers conclude: "Our findings suggest that inpatient initiation of lipid-lowering therapy for the secondary prevention of coronary disease is an effective strategy to enhance subsequent use. Other modifiable factors that influence the long-term use of these agents must be identified if we are to bridge the gap between the current evidence base and practice of preventive medicine."
(Arch Intern Med. 2003;163:2576-2582. Available post-embargo at

Editor's Note: The EPILOG trial was funded by Centocor, Malvern, Pa., and Eli Lilly and Co., Indianapolis, Ind.

For more information, contact JAMA/Archives Media Relations at 312-464-JAMA (5262) or e-mail .

The JAMA Network Journals

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to